Early Prostate Cancer 2005 New 2005 data

Abstract

The Early Prostate Cancer (EPC) Program consists of three randomised, double blind, placebo-controlled trials that assess bicalutamide either as adjuvant to treatment of curative intent or alone (radical prostatectomy, radiotherapy or watchful waiting) in patients with non-metastatic prostate cancer. In total, 8113 men have been enrolled in a 1/1 ratio to receive bicalutamide 150 mg/day orally or a matching placebo. We present the results at a median follow-up. No significant results are yet observed on overall survival in the localised, low-risk disease groups. For patients with locally advanced disease, adjuvant hormonal therapy significantly improves objective progression-free survival over placebo. Moreover, adjuvant bicalutamide offers a significant benefit in terms of overall survival in radiotherapy treated patients for locally advanced prostate cancer.